SCHEMBL10105500

SCHEMBL10105500

CCc1ccc(N(/N=C/c2ccc(N(CC)CC)cc2)c2ccc(CC)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 16/20 0.56
GAA P10253 9/20 0.56
KDM4E B2RXH2 9/20 0.56
ALDH3A1 P30838 1/20 0.49
ALDH1A3 P47895 1/20 0.49
MAPT P10636 14/20 0.46
MAPK1 P28482 4/20 0.46
HTT P42858 2/20 0.46
HPGD P15428 3/20 0.46
GFER P55789 2/20 0.46
GLA P06280 1/20 0.46
RAB9A P51151 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 5/20 0.44
TDP1 Q9NUW8 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13125573 0.94 ALDH1A1 (0.52) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL14488628 0.88 ALDH1A1 (0.57) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL122070 0.85 MAPT (0.61) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL10062466 0.85 ALDH1A1 (0.42) ALDH1A1GAAKDM4EMAPTMAPK1
SCHEMBL122069 0.85 MAPT (0.61) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL13681243 0.85 ALDH1A1 (0.50) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL278973 0.85 ALDH1A1 (0.54) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL13657541 0.85 ALDH1A1 (0.54) ALDH1A1GAAKDM4EALDH3A1ALDH1A3
SCHEMBL12572177 0.83 MEN1 (0.49) ALDH1A1GAAMAPTMAPK1HTT
SCHEMBL10062464 0.83 G6PC1 (0.47) ALDH1A1GAAKDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389060-B2 Process for preparing structured organic films (SOFs) via a pre-SOF XEROX CORPORATION (US) 2013-03-05 US disclosed
US-8093347-B2 Structured organic films XEROX CORPORATION (US) 2012-01-10 US disclosed
US-20100227071-A1 PROCESS FOR PREPARING STRUCTURED ORGANIC FILMS (SOFS) VIA A PRE-SOF XEROX CORPORATION (US) 2010-09-09 US disclosed
US-20100227998-A1 STRUCTURED ORGANIC FILMS XEROX CORPORATION (US) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227998-A1 STRUCTURED ORGANIC FILMS VIM, PUF60, EPCAM ALDH1A1 1213/4885GAA 2735/4885KDM4E 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.